Boston Common Asset Management LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 129.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,715 shares of the medical research company's stock after acquiring an additional 28,004 shares during the quarter. Boston Common Asset Management LLC's holdings in Amgen were worth $15,489,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in AMGN. Centricity Wealth Management LLC purchased a new position in Amgen during the fourth quarter valued at approximately $25,000. Pinney & Scofield Inc. bought a new position in Amgen during the fourth quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE increased its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC purchased a new position in Amgen in the 4th quarter worth about $34,000. Finally, Atala Financial Inc bought a new position in Amgen during the 4th quarter worth about $34,000. 76.50% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
AMGN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Piper Sandler lowered their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. UBS Group restated a "neutral" rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $309.22.
Check Out Our Latest Stock Report on AMGN
Amgen Stock Performance
Shares of NASDAQ:AMGN traded down $0.97 during trading on Monday, hitting $287.22. 1,006,312 shares of the stock traded hands, compared to its average volume of 2,799,837. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market cap of $154.44 billion, a price-to-earnings ratio of 38.09, a P/E/G ratio of 2.63 and a beta of 0.51. The company has a fifty day moving average price of $283.46 and a two-hundred day moving average price of $285.23. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same quarter last year, the company earned $3.96 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.31%. Amgen's dividend payout ratio (DPR) is presently 86.86%.
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
